News & Events

News

All categories

Earnings

Press Release

All years

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas

November 22, 2021

Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing

November 12, 2021

Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress

November 10, 2021

Affimed to Present at Upcoming Investor Conferences

November 9, 2021

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

November 8, 2021

Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia

November 4, 2021

Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13

November 4, 2021

Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

October 29, 2021

Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

October 1, 2021

Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

September 8, 2021

Events

All

Scientific

Investors

11Dec

ASH ANNUAL MEETING & EXPOSITION

December 11 - 14, 2021 (Georgia World Congress Center - Atlanta, GA)

29Mar

Innate Killer Summit

March 29 - April 1, 2022 (San Diego, CA)

Webcasts
More events